269 related articles for article (PubMed ID: 20969748)
21. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.
Espinosa I; Catasus L; Canet B; D'Angelo E; Muñoz J; Prat J
Mod Pathol; 2011 Jun; 24(6):846-54. PubMed ID: 21317880
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
23. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
[TBL] [Abstract][Full Text] [Related]
25. [Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues].
Yang Y; Hou JQ; Qu LY; Wang GQ; Ju HW; Zhao ZW; Yu ZH; Yang HJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jun; 23(6):504-6. PubMed ID: 17553343
[TBL] [Abstract][Full Text] [Related]
26. Gene expression patterns that characterize advanced stage serous ovarian cancers.
Lancaster JM; Dressman HK; Whitaker RS; Havrilesky L; Gray J; Marks JR; Nevins JR; Berchuck A
J Soc Gynecol Investig; 2004 Jan; 11(1):51-9. PubMed ID: 14706684
[TBL] [Abstract][Full Text] [Related]
27. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
28. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
[TBL] [Abstract][Full Text] [Related]
29. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
Choi CH; Choi JJ; Park YA; Lee YY; Song SY; Sung CO; Song T; Kim MK; Kim TJ; Lee JW; Kim HJ; Bae DS; Kim BG
Br J Cancer; 2012 Jun; 107(1):91-9. PubMed ID: 22644307
[TBL] [Abstract][Full Text] [Related]
30. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
31. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
32. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
Cuello MA; Kato S; Liberona F
J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
35. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
Callahan MJ; Nagymanyoki Z; Bonome T; Johnson ME; Litkouhi B; Sullivan EH; Hirsch MS; Matulonis UA; Liu J; Birrer MJ; Berkowitz RS; Mok SC
Clin Cancer Res; 2008 Dec; 14(23):7667-73. PubMed ID: 19047092
[TBL] [Abstract][Full Text] [Related]
36. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
37. Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
Ono K; Tanaka T; Tsunoda T; Kitahara O; Kihara C; Okamoto A; Ochiai K; Takagi T; Nakamura Y
Cancer Res; 2000 Sep; 60(18):5007-11. PubMed ID: 11016619
[TBL] [Abstract][Full Text] [Related]
38. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.
Donninger H; Bonome T; Radonovich M; Pise-Masison CA; Brady J; Shih JH; Barrett JC; Birrer MJ
Oncogene; 2004 Oct; 23(49):8065-77. PubMed ID: 15361855
[TBL] [Abstract][Full Text] [Related]
39. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
[TBL] [Abstract][Full Text] [Related]
40. [Expression and clinical significance of ELOVL6 gene in high-grade serous ovarian carcinoma].
Li FJ; Wang HY; Feng XL; Li PP; Shu T; Zhao XH; Li B
Zhonghua Fu Chan Ke Za Zhi; 2016 Mar; 51(3):192-7. PubMed ID: 27030498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
